National Healthcare Properties
NHP
15.39
-0.27
-1.72%
National Healthcare Properties
US · NHP
#3167 by market cap
Listed 2026
15.39
-0.27
-1.72%
Live - 5344 symbols - heartbeat 5s ago
· 2026-10-07 19:54
After-hours
15.39
0.00%
- Market cap
- 1.12B
- P/E (TTM)i
- -19.48
- P/Bi
- 1.06
- EPSi
- -1.05
- Div yieldi
- 0.00%
- 52W posi
- 67%
Reader sentiment
Are you bullish or bearish on NHP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -1.04, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -3.25% YoY
Margins
- Gross margin
- 36.05%
- Operating margin
- 6.11%
- Net margin
- -20.76%
Key ratios & quality
- Enterprise valuei
- 2.10B
- Altman Z-Scorei
- -1.04
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 362.41M | 374.91M | 381.61M | 329.36M | 335.85M | 345.93M | 353.79M | 342.28M |
| Gross profit | 141.41M | 140.73M | 138.06M | 123.54M | 122.40M | 128.13M | 132.34M | 123.38M |
| Selling & admin expenses | 17.28M | 20.53M | 21.57M | 16.83M | 17.29M | 18.93M | 22.44M | 24.19M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 17.85M | 15.75M | 11.52M | 2.58M | -2.30M | 805.00K | 6.63M | 20.93M |
| Pretax profit | -52.78M | -87.91M | -71.45M | -85.24M | -79.42M | -72.08M | -190.00M | -57.52M |
| Tax | 197.00K | 399.00K | 4.06M | 203.00K | 201.00K | 303.00K | 262.00K | 161.00K |
| Net profit | -52.98M | -88.31M | -75.51M | -85.44M | -79.62M | -72.38M | -190.26M | -57.69M |
| Basic EPS | -2 | -1 | -1 | -1 | -3 | -3 | -7 | -3 |
| Diluted EPS | -1.86 | -0.88 | -0.74 | -0.82 | -3.30 | -3.04 | -7.19 | -2.51 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 86.44M | 85.33M | 86.03M | 84.48M | 86.29M | 87.53M |
| Gross profit | 28.59M | 31.15M | 32.18M | 31.46M | 33.37M | 33.41M |
| Selling & admin expenses | 4.90M | 5.08M | 5.67M | 8.55M | 5.47M | 6.60M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -15.00K | 7.54M | 8.48M | 4.93M | 10.16M | 9.00M |
| Pretax profit | -1.52M | -20.83M | -12.47M | -22.70M | -4.20M | -5.34M |
| Tax | -6.00K | 0 | 66.00K | 101.00K | 77.00K | 47.00K |
| Net profit | -1.52M | -20.83M | -12.53M | -22.80M | -4.28M | -5.39M |
| Basic EPS | 0 | -1 | -1 | -1 | 0 | 0 |
| Diluted EPS | -0.18 | -0.85 | -0.56 | -0.92 | -0.27 | -0.13 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 203.62M | 113.76M | 109.24M | 101.81M | 117.64M | 102.79M | 139.19M |
| Cash & ST investments | -- | 95.69M | 72.36M | 59.74M | 53.65M | 46.41M | 21.65M | 57.62M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 2.33B | 2.29B | 2.21B | 2.18B | 2.15B | 1.95B | 1.71B |
| Total current liabilities | -- | 663.79M | 724.48M | 556.79M | 584.97M | 419.38M | 462.50M | 577.71M |
| Short-term debt | -- | 605.27M | 674.55M | 502.05M | 530.30M | 361.03M | 362.22M | 520.74M |
| Long-term debt | -- | 528.28M | 542.70M | 584.24M | 578.70M | 809.00M | 779.16M | 516.03M |
| Total liabilities | -- | 1,218,559,000.00 | 1,325,523,000.00 | 1,174,000,000.00 | 1,181,159,000.00 | 1,244,576,000.00 | 1,255,898,000.00 | 1,107,247,000.00 |
| Total equity | -- | 1.11B | 961.37M | 1.04B | 999.19M | 900.58M | 690.13M | 604.53M |
| Retained earnings | -- | -971.19M | -1.11B | -1.28B | -1.46B | -1.64B | -1.87B | -1.94B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 154.47M | 134.52M | 140.06M | 139.19M | 137.55M | 331.46M |
| Cash & ST investments | 71.38M | 47.12M | 47.06M | 57.62M | 52.81M | 245.70M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.83B | 1.76B | 1.74B | 1.71B | 1.70B | 1.98B |
| Total current liabilities | 427.19M | 396.73M | 396.22M | 577.71M | 238.97M | 58.10M |
| Short-term debt | 360.77M | 337.62M | 336.18M | 520.74M | 186.00M | -- |
| Long-term debt | 711.07M | 696.51M | 696.81M | 516.03M | 849.56M | 848.16M |
| Total liabilities | 1,151,765,000.00 | 1,106,414,000.00 | 1,106,409,000.00 | 1,107,247,000.00 | 1,101,519,000.00 | 919,050,000.00 |
| Total equity | 680.12M | 652.48M | 632.65M | 604.53M | 596.54M | 1.06B |
| Retained earnings | -1.87B | -1.90B | -1.91B | -1.94B | -1.95B | -1.95B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 54.15M | 47.40M | 41.81M | 38.88M | 28.30M | 21.62M | -79.85M | 6.95M |
| Depreciation & amortization | 83.47M | 81.03M | 80.97M | 79.73M | 81.44M | 82.87M | 84.07M | 78.26M |
| Free cash flow | 41.24M | 30.69M | 19.92M | 19.81M | 302.00K | -773.00K | -101.75M | -21.78M |
| Dividends paid | -55.33M | -51.43M | -33.75M | -5.14M | -13.80M | -13.80M | -13.80M | -13.45M |
| Stock buybacks / issuance | -14.20M | -21.11M | -10.54M | -- | -- | -- | -- | -- |
| Ending cash balance | 91.36M | 111.60M | 90.35M | 85.38M | 76.54M | 91.32M | 74.10M | 108.45M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -21.23M | 8.05M | 10.17M | 9.96M | 9.01M | 21.61M |
| Depreciation & amortization | 23.71M | 18.54M | 18.03M | 17.99M | 17.74M | 17.81M |
| Free cash flow | -26.90M | 1.36M | 5.58M | -1.81M | 3.75M | 16.26M |
| Dividends paid | -3.45M | -3.38M | -3.33M | -3.28M | -3.29M | -3.29M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 126.41M | 103.17M | 102.54M | 108.45M | 106.60M | 302.38M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -8.00 | -7.66 | -9.34 | -9.21 | -9.13 | -25.78 | -11.07 |
| ROA %i | -- | -3.79 | -3.42 | -4.13 | -4.25 | -3.98 | -9.95 | -3.89 |
| ROIC %i | -- | -2.10 | -1.86 | -2.69 | -2.59 | -1.80 | -7.81 | -1.47 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -8.67 | -12.22 | -12.90 |
| EBIT margin %i | -0.91 | -8.50 | -5.22 | -11.34 | -8.24 | -1.73 | -34.07 | 1.10 |
| FCF / sales %i | 11.38 | 8.18 | 5.22 | 6.01 | 0.09 | -- | -- | -- |
| Current ratioi | -- | 0.31 | 0.16 | 0.20 | 0.17 | 0.28 | 0.22 | 0.24 |
| Quick ratioi | -- | 0.18 | 0.13 | 0.15 | 0.13 | 0.17 | 0.11 | 0.15 |
| Debt / assetsi | -- | 49.14 | 53.63 | 49.42 | 51.23 | 54.92 | 59.07 | 61.06 |
| LT debt / equityi | -- | 48.80 | 57.67 | 57.31 | 59.12 | 91.38 | 115.02 | 87.42 |
| Interest coveragei | -0.07 | -0.57 | -0.39 | -0.78 | -0.53 | -0.09 | -1.74 | 0.06 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -3.14 | -3.60 | -3.22 | 2.41 | 0.63 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -21.69 | -78.57 | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -24.42 | -13.36 | -9.86 | -11.07 | -11.63 | -6.77 |
| ROA %i | -9.56 | -4.84 | -3.51 | -3.89 | -4.17 | -3.08 |
| ROIC %i | -7.30 | -2.50 | -1.08 | -1.47 | -2.17 | -1.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -30.81 | -4.12 | 3.19 | 1.10 | 0.35 | 3.95 |
| FCF / sales %i | -- | -- | -- | -- | 2.59 | 6.91 |
| Current ratioi | 0.36 | 0.34 | 0.35 | 0.24 | 0.58 | 5.71 |
| Quick ratioi | 0.23 | 0.19 | 0.20 | 0.15 | 0.35 | 4.73 |
| Debt / assetsi | 58.94 | 59.24 | 59.87 | 61.06 | 61.75 | 43.56 |
| LT debt / equityi | 106.58 | 108.86 | 112.43 | 87.42 | 145.68 | 81.68 |
| Interest coveragei | -1.60 | -0.22 | 0.18 | 0.06 | 0.02 | 0.23 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Senior housing operating properties (SHOPs) is the largest reported line at 66.66% of revenue, across 2 reported segments.
- Outpatient medical facilities (OMFs) follows at 33.34%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Senior housing operating properties (SHOPs)66.66%
Outpatient medical facilities (OMFs)33.34%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.